Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic l
about
Recent advances and novel treatment paradigms in acute lymphocytic leukemiaBurkitt lymphoma in adolescents and young adults: management challenges.New Therapeutic Strategies in Acute Lymphocytic Leukemia.Targeting CD157 in AML using a novel, Fc-engineered antibody construct.Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemiaDriving Toward Precision Medicine for Acute Leukemias: Are We There Yet?Microheterogeneity of therapeutic monoclonal antibodies is governed by changes in the surface charge of the protein.Immunotherapy approaches to treat adult acute lymphoblastic leukemia.Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.The development of targeted new agents to improve the outcome for children with leukemia.Anti-CD20 monoclonal antibodies in multiple sclerosis.Novel therapy for childhood acute lymphoblastic leukemia.Acute lymphoblastic leukemia: a comprehensive review and 2017 updateControl of NK Cell Activation by Immune Checkpoint Molecules.The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia.Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study.A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment.S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up (ICD10 C82 - C86).S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 2: Therapie und Nachsorge (ICD10 C82 - C86).[Treatment of indolent cutaneous B‑cell lymphoma].Cutaneous B-cell lymphomas - pathogenesis, diagnostic workup, and therapy.Tumor immunotherapy: New aspects of natural killer cells.Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.
P2860
Q28078076-FABAC4E6-96DD-4D70-8788-758A0FBD2222Q30238965-E063400B-FAD7-4922-BC07-C012D2CCA011Q30252776-7DBBBD08-886C-412B-8534-56001EE08698Q33829283-D7F0FFE3-D278-445D-8D4F-5145C691F57DQ38640263-FB634489-3F81-4018-B5BC-CE0D9528D232Q38666159-5FE840CA-26A9-45BE-AACF-D08C2DF9AF38Q38740314-007CB715-21A8-4DF1-A51B-B7992E47AE9CQ38787405-64020EC0-CB08-4443-8AC4-5D745354D3E7Q38803361-EE98981A-C631-4741-859A-992C7CFA6662Q38964974-5CDABC28-B7F2-4775-8DD9-0C80736F234FQ38975695-76EDC059-7A8B-4C5E-9FC1-7E9B91C70A1CQ39368957-BDF372E0-F7B5-4BD4-A28D-979742A5CC45Q39406969-21830C59-8975-40F4-912F-E11C3635C2C3Q47128718-E37A1D0F-3ABA-4741-88F0-CE9C889B54A4Q47809709-DB7F657A-3B24-442D-901A-9A226243BE65Q48192887-D11EFB03-3B94-44AA-B373-AA7FCE3D9A62Q48263835-55B801C5-7E1D-4F7B-94C1-B91E45AD3406Q49177202-54C6D81F-E1F2-4762-9C11-F26469E0EAB6Q49561302-E941B247-ACBA-4D28-A3BA-61FFA17FFA9EQ50122599-C83A8303-2537-4D7B-A25C-62ABB8DFBF97Q53130617-AF6225BA-9031-4822-98BA-C70994ADC098Q54205796-2F0EF478-9200-4D2E-84AA-E9E07C9D3B73Q55107050-78B902EC-CEB3-47C4-8C81-D8E1E92C53B7Q55283747-63FCD492-7C92-4A18-9EFB-304668038E9C
P2860
Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic l
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Obinutuzumab (GA101) compared ...... cursor B-acute lymphoblastic l
@en
type
label
Obinutuzumab (GA101) compared ...... cursor B-acute lymphoblastic l
@en
prefLabel
Obinutuzumab (GA101) compared ...... cursor B-acute lymphoblastic l
@en
P2093
P2860
P921
P356
P1476
Obinutuzumab (GA101) compared ...... cursor B-acute lymphoblastic l
@en
P2093
Anthony Sabulski
Aradhana Awasthi
Carmella Van de Ven
Christian Klein
Humayun Islam
Janet Ayello
Matthew J Barth
Mitchell S Cairo
Mona Elmacken
Myron S Czuczman
P2860
P304
P356
10.1111/BJH.13764
P407
P577
2015-10-16T00:00:00Z